Patents by Inventor James Allen Monn

James Allen Monn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist
    Patent number: 9296710
    Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, and generalized anxiety disorder.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: March 29, 2016
    Assignee: Eli Lilly and Company
    Inventors: Teresa Tse Ki Man, James Allen Monn, Carlos Montero Salgado, Lourdes Prieto, David Edward Tupper, Lesley Walton
  • BICYCLO (3.1.0) HEXANE-2, 6-DICARBOXYLIC ACID DERIVATIVES AS MGLU2 RECEPTOR AGONIST
    Publication number: 20140113944
    Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, and generalized anxiety disorder.
    Type: Application
    Filed: June 7, 2012
    Publication date: April 24, 2014
    Applicant: ELI LILLY AND COMPANY
    Inventors: Teresa Tse Ki Man, James Allen Monn, Carlos Montero Salgado, Lourdes Prieto, David Edward Tupper, Lesley Walton
  • MGlu 2/3 agonists
    Patent number: 8575214
    Abstract: The present invention provides novel mGlu2/3 agonists of the formula wherein R1, R2, and R3 are as defined herein, for use in the treatment of neurological or psychiatric disorders.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: November 5, 2013
    Assignee: Eli Lilly and Company
    Inventors: Stephen Richard Baker, Christopher David Beadle, Barry Peter Clark, James Allen Monn, Lourdes Prieto
  • MGLU2 agonists
    Patent number: 8318184
    Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: November 27, 2012
    Assignee: Eli Lilly and Company
    Inventors: James Allen Monn, Lourdes Prieto, Lorena Taboada Martinez, Carlos Montero Salgado, Bruce William Shaw
  • Methods of Treatment Using a Prodrug of an Excitatory Amino Acid
    Publication number: 20120172422
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: March 13, 2012
    Publication date: July 5, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Eric David Moher, James Allen Monn, Concepcion Pedregal-Tercero, Jaime Gonzalo Blanco-Urgoiti, Ivan Collado Cano
  • Methods of treatment using a prodrug of an excitatory amino acid
    Patent number: 8153683
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: April 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Eric David Moher, James Allen Monn
  • METHODS OF TREATMENT USING A PRODRUG OF AN EXCITATORY AMINO ACID
    Publication number: 20110207672
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: May 4, 2011
    Publication date: August 25, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Eric David Moher, James Allen Monn, Concepcion Pedregal-Tercero, Jaime Gonzalo Blanco-Urgoiti, Ivan Collado Cano
  • MGLU2 AGONISTS
    Publication number: 20110152334
    Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder.
    Type: Application
    Filed: December 15, 2010
    Publication date: June 23, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: James Allen MONN, Lourdes PRIETO, Lorena TABOADA MARTINEZ, Carlos Montero SALGADO, Bruce William SHAW
  • Methods of treatment using a prodrug of an excitatory amino acid
    Patent number: 7964632
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: June 21, 2011
    Assignee: Eli Lilly and Company
    Inventors: Eric David Moher, James Allen Monn, Concepcion Pedregal-Tercero, Ivan Collado Caño, Jaime Gonzalo Blanco-Urgoiti
  • Pyridyl derivatives and their use as mGlu5 antagonists
    Patent number: 7915424
    Abstract: The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: March 29, 2011
    Assignee: Eli Lilly and Company
    Inventors: Francisco Javier Agejas-Chicharro, Bruce Anthony Dressman, Jose Antonio Martinez Perez, James Allen Monn, Mohammad Sadegh Zia-Ebrahimi, Sonia Gutierrez Sanfeliciano, Steven Marc Massey, Steven Scott Henry
  • PRODRUGS OF EXCITATORY AMINO ACIDS
    Publication number: 20100113579
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: January 15, 2010
    Publication date: May 6, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Eric David Moher, James Allen Monn, Concepcion Pedregal-Tercero, Jaime Gonzalo Blanco-Urgoiti, Ivan Collado Cano
  • Prodrugs of excitatory amino acids
    Patent number: 7671082
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: March 2, 2010
    Assignee: Eli Lilly and Company
    Inventors: Eric David Moher, James Allen Monn
  • Prodrugs of excitatory amino acids
    Patent number: 7456221
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: November 25, 2008
    Assignee: Eli Lilly and Company
    Inventors: David Scott Coffey, James Allen Monn, Concepcion Pedregal-Tercero, Steven Wayne Pedersen
  • Pyridyl Derivatives and Their Use as Mglu5 Antagonists
    Publication number: 20080194647
    Abstract: The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor.
    Type: Application
    Filed: March 9, 2005
    Publication date: August 14, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Francisco Javier Agejas-Chicharro, Anthony Bruce Dressman, Sonia Gutierrez Sanfeliciano, Steven Scott Henry, Jose Antonio Martinez Perez, Steven Marc Massey, James Allen Monn, Mohammad Sadegh Zia-Ebrahimi
  • PRODRUGS OF EXCITATORY AMINO ACIDS
    Publication number: 20080182889
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: March 31, 2008
    Publication date: July 31, 2008
    Inventors: Eric David Moher, James Allen Monn, Concepcion Pedregal-Tercero, Jaime Gonzalo Blanco-Urgoiti, Ivan Collado Cano
  • Prodrugs of excitatory amino acids
    Patent number: 7371872
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: May 13, 2008
    Assignee: Eli Lilly and Company
    Inventors: Eric David Moher, James Allen Monn
  • Prodrugs of excitatory amino acids
    Patent number: 7256217
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs according to formula (I) and processes for their preparation.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: August 14, 2007
    Assignee: Eli Lilly and Company
    Inventors: David Scott Coffey, James Allen Monn, Concepcion Pedregal-Tercero, Steven Wayne Pedersen
  • Excitatory amino acid receptor modulators
    Patent number: 7125871
    Abstract: Compounds of the formula (I) in which R1, R2 and X1 have the meanings given in the specification, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: October 24, 2006
    Assignee: Eli Lilly and Company
    Inventors: Ivan Collado Cano, Jesus Ezquerra-Carrera, Alicia Marcos Liorente, Luisa Maria Martin-Cabrejas, James Allen Monn
  • Prodrugs of excitatory amino acids
    Patent number: 7038077
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: May 2, 2006
    Assignee: Eli Lilly and Company
    Inventors: Anne Hollins Dantzig, James Allen Monn, Stephanie Ann Sweetana, Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Marc Francis Herin, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Maria Angeles Martinez-Grau, Carlos Montero Salgado, Concepcion Pedregal-Tercero
  • Prodrugs of excitatory amino acids
    Publication number: 20040248963
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs of formula (I) wherein the residues R11, R12 and R13 are as defined in claim 1. The invention further relates to processes for the preparation of the compounds of formula (I), and to pharmaceutical compositions for the treatment of neurological and psychiatric disorders comprising said compounds.
    Type: Application
    Filed: April 30, 2004
    Publication date: December 9, 2004
    Inventors: Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Mark Francis Herin, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Maria Angeles Martinez-Grau, Steven Marc Massey, James Allen Monn, Carlos Montero Salgado, Concepcion Pedregal-Tercero, Matthew John Valli